JP2015520146A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520146A5 JP2015520146A5 JP2015510925A JP2015510925A JP2015520146A5 JP 2015520146 A5 JP2015520146 A5 JP 2015520146A5 JP 2015510925 A JP2015510925 A JP 2015510925A JP 2015510925 A JP2015510925 A JP 2015510925A JP 2015520146 A5 JP2015520146 A5 JP 2015520146A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- alkyl
- compound
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- -1 6-methylheptan-2-yl Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical group 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 125000003367 polycyclic group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims 2
- OYXZMSRRJOYLLO-UHFFFAOYSA-N 7alpha-Hydroxycholesterol Natural products OC1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 OYXZMSRRJOYLLO-UHFFFAOYSA-N 0.000 claims 2
- OYXZMSRRJOYLLO-KGZHIOMZSA-N 7beta-hydroxycholesterol Chemical compound C([C@@H]1O)=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 OYXZMSRRJOYLLO-KGZHIOMZSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 125000000468 ketone group Chemical group 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- SIJBDWPVNAYVGY-UHFFFAOYSA-N 2,2-dimethyl-1,3-dioxolane Chemical compound CC1(C)OCCO1 SIJBDWPVNAYVGY-UHFFFAOYSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000001980 alanyl group Chemical group 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 1
- 210000001130 astrocyte Anatomy 0.000 claims 1
- 239000003833 bile salt Substances 0.000 claims 1
- 229940093761 bile salts Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000006196 drop Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002073 methionyl group Chemical group 0.000 claims 1
- MCLPGRDSFRGNHK-UHFFFAOYSA-N phenanthren-3-yl 2,2-dimethyl-1,3-dioxolane-4-carboxylate Chemical compound CC1(OCC(O1)C(=O)OC=1C=CC=2C=CC3=CC=CC=C3C=2C=1)C MCLPGRDSFRGNHK-UHFFFAOYSA-N 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000011450 sequencing therapy Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305518.8A EP2662382B1 (fr) | 2012-05-10 | 2012-05-10 | Dérivés de stérol, leur procédé de préparation, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement du glioblastome multiple |
| EP12305518.8 | 2012-05-10 | ||
| US201261656151P | 2012-06-06 | 2012-06-06 | |
| US61/656,151 | 2012-06-06 | ||
| PCT/IB2013/053669 WO2013168096A1 (en) | 2012-05-10 | 2013-05-07 | Sterol derivatives and use thereof for treating diseases involving transformed astrocyte cells or for treating malignant haemopathies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520146A JP2015520146A (ja) | 2015-07-16 |
| JP2015520146A5 true JP2015520146A5 (cg-RX-API-DMAC10.html) | 2016-06-30 |
| JP6270823B2 JP6270823B2 (ja) | 2018-01-31 |
Family
ID=46149353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510925A Active JP6270823B2 (ja) | 2012-05-10 | 2013-05-07 | ステロール誘導体、及び形質転換した星状膠細胞に関係する疾患を治療するため、または悪性血液疾患を治療するためのその使用 |
Country Status (23)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3013048A1 (fr) * | 2013-11-12 | 2015-05-15 | Beta Innov | Derive de sterol, son procede de preparation, composition pharmaceutique le contenant et son utilisation pour le traitement du glioblastome multiforme |
| EP3593789A1 (fr) * | 2018-07-11 | 2020-01-15 | Beta Innov | Composition contenant un dérivé de 7beta-hydroxycholestérol et un véhicule lipidique, et son utilisation dans le traitement de pathologies néoplasiques |
| KR102689231B1 (ko) * | 2021-05-18 | 2024-07-30 | 연세대학교 산학협력단 | 암의 예방, 개선 또는 치료용 조성물 |
| KR102748745B1 (ko) * | 2021-05-18 | 2025-01-03 | 연세대학교 산학협력단 | 암의 예방, 개선 또는 치료용 조성물 |
| WO2024030660A2 (en) * | 2022-08-04 | 2024-02-08 | University Of Massachusetts | Cholesterol-modified hyaluronic acids |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9602100D0 (sv) * | 1996-05-30 | 1996-05-30 | Magnus Axelson | New pharmaceuticals |
| JP2006503840A (ja) * | 2002-09-25 | 2006-02-02 | フォーブス メディ−テック インコーポレーテッド | ステロール及び／又はスタノール及び抗炎症剤の特定の種類を含有する新規構造体及び組成物、並びに、心血管疾患、その根底にある高脂血症を含む病気、及び原因又は症状の一部として炎症を有する他の障害の治療又は予防におけるそれらの使用 |
-
2012
- 2012-05-10 EP EP12305518.8A patent/EP2662382B1/fr active Active
- 2012-05-10 DK DK12305518.8T patent/DK2662382T3/en active
- 2012-05-10 ME MEP-2016-134A patent/ME02436B/me unknown
- 2012-05-10 HU HUE12305518A patent/HUE029243T2/en unknown
- 2012-05-10 RS RS20160499A patent/RS54926B1/sr unknown
- 2012-05-10 ES ES12305518.8T patent/ES2580331T3/es active Active
- 2012-05-10 PT PT123055188T patent/PT2662382T/pt unknown
- 2012-05-10 SI SI201230585A patent/SI2662382T1/sl unknown
- 2012-05-10 PL PL12305518.8T patent/PL2662382T3/pl unknown
-
2013
- 2013-05-07 LT LTEP13729470.8T patent/LT2847204T/lt unknown
- 2013-05-07 SI SI201330962T patent/SI2847204T1/en unknown
- 2013-05-07 RU RU2014149705A patent/RU2627710C2/ru active
- 2013-05-07 CN CN201380023824.4A patent/CN104302655B/zh active Active
- 2013-05-07 TR TR2018/02700T patent/TR201802700T4/tr unknown
- 2013-05-07 HR HRP20180345TT patent/HRP20180345T1/hr unknown
- 2013-05-07 CA CA2871714A patent/CA2871714C/en active Active
- 2013-05-07 JP JP2015510925A patent/JP6270823B2/ja active Active
- 2013-05-07 US US14/399,336 patent/US10800806B2/en active Active
- 2013-05-07 WO PCT/IB2013/053669 patent/WO2013168096A1/en not_active Ceased
- 2013-05-07 PT PT137294708T patent/PT2847204T/pt unknown
- 2013-05-07 ES ES13729470.8T patent/ES2662123T3/es active Active
- 2013-05-07 KR KR1020147034290A patent/KR102160316B1/ko active Active
- 2013-05-07 HU HUE13729470A patent/HUE037004T2/hu unknown
- 2013-05-07 PL PL13729470T patent/PL2847204T3/pl unknown
- 2013-05-07 IN IN9437DEN2014 patent/IN2014DN09437A/en unknown
- 2013-05-07 BR BR112014026948-3A patent/BR112014026948B1/pt active IP Right Grant
- 2013-05-07 RS RS20180237A patent/RS57065B1/sr unknown
- 2013-05-07 EP EP13729470.8A patent/EP2847204B1/en active Active
- 2013-05-07 SM SM20180147T patent/SMT201800147T1/it unknown
- 2013-05-07 DK DK13729470.8T patent/DK2847204T3/en active
-
2016
- 2016-06-07 HR HRP20160624TT patent/HRP20160624T1/hr unknown
- 2016-07-05 SM SM201600215T patent/SMT201600215B/it unknown
- 2016-07-05 CY CY20161100621T patent/CY1117723T1/el unknown
-
2018
- 2018-03-13 CY CY20181100306T patent/CY1120395T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7032583B2 (ja) | アルギナーゼ活性を阻害する組成物及び方法 | |
| JP6480025B2 (ja) | イオン性化合物及び組成物並びにその使用 | |
| EP3229810B1 (en) | Phospholipid ether analogs as cancer-targeting drug vehicles | |
| CA2669913C (en) | Endoxifen methods and compositions | |
| JP2015520146A5 (cg-RX-API-DMAC10.html) | ||
| TW202308658A (zh) | 異喹啉穩定之脂質奈米粒子調配物 | |
| EP2672974A1 (en) | Hybrid opioid compounds and compositions | |
| WO2014138425A1 (en) | Cyclosporine a-steroid conjugates | |
| AU2007328007A1 (en) | Prodrugs and methods of making and using the same | |
| JP2008508357A5 (cg-RX-API-DMAC10.html) | ||
| JP2019196380A (ja) | Ｍｈｃ−ｉの発現を増加させるためのクルクフェノール化合物 | |
| JP2025087716A (ja) | 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート | |
| JP5011113B2 (ja) | 抗癌剤 | |
| RU2014149705A (ru) | Производные стеринов и их применение для лечения заболеваний, связанных с трансформированными астроцитными клетками, или для лечения злокачественных заболеваний крови | |
| TWI837128B (zh) | 萘普生(ｎａｐｒｏｘｅｎ)及普加巴林(ｐｒｅｇａｂａｌｉｎ)之1-(醯氧基)-烷基胺甲酸酯之藥物結合物的結晶型 | |
| JP7630193B2 (ja) | １，２，４，５－テトラオキサン化合物の標的化送達及びその使用 | |
| EP3286198B1 (en) | Compounds for treating pruritic conditions | |
| RU2799809C2 (ru) | Кристаллические формы 1-(ацилокси)-алкилкарбаматных конъюгатов лекарственных средств напроксена и прегабалина | |
| CN116887825A (zh) | 含有格隆铵·水杨酸盐的药物 | |
| BR112020022885B1 (pt) | Processo para preparar um composto e composto | |
| JP2007512258A5 (cg-RX-API-DMAC10.html) | ||
| JP2024503572A (ja) | 癌の治療に使用するための５α－ヒドロキシ－６β－［２－（１ｈ－イミダゾール－４－イル）エチルアミノ］－コレスタン－３β－オールのプロドラッグおよびそれを含む医薬組成物 | |
| WO2008022128A2 (en) | Transdermal delivery of meptazinol |